Myriad Genetics (MYGN) Cash from Financing Activities (2009 - 2026)

Myriad Genetics (MYGN) has reported Cash from Financing Activities for 18 consecutive years, with -$3.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 122.06% year-over-year to -$3.0 million; the TTM figure through Mar 2026 stood at $47.6 million (up 217.33% YoY), while the FY2025 annual figure was $64.2 million, up 967.57% from the prior year.
• Cash from Financing Activities climbed to -$3.0 million in Q1 2026 per MYGN's latest filing, from -$8.2 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $121.9 million in Q4 2023 and bottomed at -$8.8 million in Q1 2024.
• Historically, Cash from Financing Activities has averaged $11.7 million across 5 years, with a median of -$2.1 million in 2022.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 5904.76% — and 2025, when it sank 490.48%.
• Myriad Genetics' Cash from Financing Activities stood at -$2.1 million in 2022, then soared by 5904.76% to $121.9 million in 2023, then tumbled by 98.28% to $2.1 million in 2024, then tumbled by 490.48% to -$8.2 million in 2025, then surged by 63.41% to -$3.0 million in 2026.
• Business Quant data shows MYGN's Cash from Financing Activities at -$3.0 million in Q1 2026, -$8.2 million in Q4 2025, and $56.2 million in Q3 2025.